Arkolith/Insider Trading/APRE/Form 4

Gilad Oren

President/CEO, DirectorAprea Therapeutics, Inc. (APRE) · full profile →Form 4 · filed Feb 2, 2026
Net Buying
Open-Market Buys
$25K
Open-Market Sells
$0
Net Open-Market Flow
$25K
Transactions
2
1 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 30, 2026Buy(P)28K$0.89$25K374K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jan 30, 2026Buy(P)28K——28K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-26-009206) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML